Answers are grounded in this paper and cite their sources.
The substituted benzimidazoles are a new class of drugs with a unique antisecretory action. These agents have great potential for treatment of acid-peptic disease because they produce substantial, long-lasting inhibition of gastric acid secretion by inhibiting gastric H+,K+-ATPase in the gastric parietal cell. Clinical trials of omeprazole, a substituted benzimidazole, indicate that it is safe and effective for short-term treatment of patients with duodenal or gastric ulcer, and it is highly effective for long-term treatment of patients with Zollinger-Ellison syndrome.
No takes yet. Share an insight, caveat, or question.
McArthur et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: